NewsRoom Articles - Page 31 of 52

MondayMay 01, 2023 11:15 am

Data443 Risk Mitigation Inc. (ATDS) Continues Winning Streak; Expands Across Financial Sector

As cyber-attacks increase in sophistication and frequency, the need for solutions to protect sensitive data has never been greater Data443 continues its string of success, securing two additional contracts with fintech clients; appears poised to expand its market footprint to include insurance, rating agencies, and large and small banks Data443 appears ahead of the curve in EFT/MFT, positioning the company for continued growth Data443 Risk Mitigation (OTC: ATDS), the "All Things Data Security" software company recently announced two contract wins from large fintech clients, growing relationships within the financial technology sector based upon their commitment to keep sensitive data safe…

ThursdayApr 27, 2023 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Unveils World’s Smallest Long-Range Lidar and Expanded Proprietary ASIC Chipset

Lidar’s perception capabilities and seamless integration into modern vehicle designs are primary challenges facing mass-market ADAS adoption CPTN’s Vista(R)-X90 Plus overcomes size and performance obstacles to enable faster ADAS mass-market commercialization CPTN recently released Komodo, an advanced point cloud processor ASIC; advantages include increased speed, improved sensor performance, higher digital signal processing, and noise reduction Production of proprietary ASIC costs 10x less than legacy alternatives and reduces supply chain vulnerabilities, enabling CPTN to offer an unparalleled cost-to-performance ratio Commercialization of lidar for Advanced Driver-Assistance Systems (“ADAS”) faces two primary obstacles: perception capabilities and sensor embeddability into modern vehicle designs. Lidar…

TuesdayApr 25, 2023 9:45 am

Making the Roads Safer with Cepton, Inc. (NASDAQ: CPTN)’s Automotive Lidar Solutions

The National Highway Traffic Safety Administration estimated pedestrian crashes accounting for $112.5 billion in total societal impact in 2019 According to Cepton, “Systems with lidar, camera & radar have been found to have the potential to prevent 98% of pedestrian fatalities” Cepton recently unveiled its new Vista(R)-X90 Plus lidar, the world’s smallest high-performance automotive lidar with software definable perception capabilities Interest in autonomous driving is high, but most drivers still aren’t comfortable with the idea of operating without human involvement. The reason, as with many new technologies, boils down to understanding. The J.D. Power 2022 Mobility Confidence Index report made…

TuesdayApr 18, 2023 10:30 am

Cepton, Inc. (NASDAQ: CPTN) Continues to Forge Innovative Partnerships to Expand Lidar Applications Across Sectors and Geographies

As a lidar developer engaged with all Top 10 global automotive OEMs, Cepton is established in the automotive space; but as a technology that allows examination of natural and manmade environments with accuracy and precision, lidar can offer much more In addition to its work with leading automotive OEMs, Cepton has been also committed to forging partnerships beyond the automotive sector to improve infrastructure efficiency and safety around the world Cepton’s low-cost, high-resolution perception devices that enable scanning of environments have been deployed in projects around the world to transform spaces into smart infrastructure Often coined as one of the…

MondayApr 17, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will…

FridayApr 14, 2023 9:45 am

Lidar Pioneer Cepton, Inc. (NASDAQ: CPTN) Bridges Technological Gaps to Advance Mass Market ADAS Adoption

Cepton unveiled its Vista(R)-X120 Plus earlier this year at CES 2023, one of the largest tech tradeshows this year, where it was named a CES 2023 innovation award honoree for next-generation lidar products Vista(R)-X120 Plus features a wider field of view, software-definable regions of interest, and faster data transmission with a target price below $500, enabling high-volume production and faster mass-market adoption Vista(R)-X120 Plus is smaller and lighter, allowing for seamless integration without significantly affecting vehicle design Cepton collaborates with many global OEMS, and recently won the largest commercial lidar deployment contract in the tolling sector to date Advanced Driver…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

TuesdayApr 11, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care The enrollment moves the company closer to its goal of undertaking an interim analysis expected in the third quarter of 2023 So far, CNS Pharmaceuticals has opened over 40 of 59 planned clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S. As an aside, the…

MondayApr 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active…

WednesdayApr 05, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform

Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000